• Deuel Conference on Lipids

    March 3–6, 2020, Hotel del Coronado, Coronado, Calif.

Program

Co-Chairs

Jay Horton

Jay Horton, University of Texas Southwestern Medical Center

Alan Tall

Alan Tall, Columbia University

Tuesday, March 3

7:30 p.m. Jennifer Lippincott-Schwartz

The Havel Lecture
Dynamics of membrane trafficking, sorting and compartmentalization within eukaryotic cells
Jennifer Lippincott-Schwartz, HHMI Janelia Research Campus

Wednesday, March 4

Session 1: Genetics of NAFLD

8:45 a.m. – 12 p.m. Joseph L. Goldstein

SREBPs and NAFLD
Joseph L. Goldstein, University of Texas Southwestern Medical Center

  Elizabeth Speliotes

Use of GWAS to identify genes causing NASH
Elizabeth Speliotes, University of Michigan

  Stefano Romeo

Identification and characterization of role of MBOAT7 in NASH
Stefano Romeo, University of Gothenburg

  Helen Hobbs

Characterization of PNPLA3 and its role in the development of NAFLD
Helen Hobbs, University of Texas Southwestern Medical Center

Session 2: Role of Lipids in NASH

6:30–9 p.m. Robert Farese

Lipid droplets and non-alcoholic fatty liver disease
Robert Farese, Harvard School of Public Health

  Ira Tabas

Hepatocyte cholesterol signaling in TAZ-induced NASH fibrosis and hepatocellular carcinoma
Ira Tabas, Columbia University

  Noura Abul-Husn

Journal of Clinical Investigation Award Lecture
Leveraging large-scale genomics and EHR-linked biobanks to understand NAFLD/NASH risk and identify novel therapeutic targets
Noura Abul-Husn, Mount Sinai School of Medicine

Thursday, March 5

Session 3: Fatty liver, TRLs and atherosclerosis

8:45 a.m. – 12 p.m. Morris Birnbaum

DGAT2 inhibition for the treatment of NASH
Morris Birnbaum, Pfizer Inc.

  Christie Ballantyne

Lessons learned from the Reduce-it trial — additional benefit for NAFLD?
Christie Ballantyne, Baylor College of Medicine

  Sam Klein

Role of de novo lipogenesis in NAFLD
Sam Klein, Washington University in St. Louis

  Susmita Kaushik

Chaperone-mediated autophagy and lipids: The fate of fat in the hands of proteins
Susmita Kaushik, Albert Einstein College of Medicine

Session 4: Fat to NASH and beyond

7:30–9 p.m. Scott Friedman

Role of lipids in stellate cell activation
Scott Friedman, Mount Sinai School of Medicine

  Utpal Pajvani

Notch activation induces NASH-associated fibrosis
Utpal Pajvani, Columbia University

  Wajabat Mehal

Innate immune signaling in NASH/ASH
Wajahat Mehal, Yale University

Friday, March 6

Session 5: Emerging Therapies for NASH

8:45 a.m. – 12 p.m. Chinweike Ukomadu

Combination therapies for NASH
Chinweike Ukomadu, Novartis Institutes for Biomedical Research

  Lei Ling

Characterization of FGF19 analogues for NASH
Lei Ling, NGM Biopharmaceuticals

  Chuhan Chung

ACC inhibition for the treatment of NASH
Chuhan Chung, Gilead Sciences, Inc.


PAST PROGRAMS